Fortrea Holdings Inc - When Issue

FRA:K67 (USA)   When Issue
€ 21.00 (+2.94%) Sep 20
At Loss
P/B:
1.46
Market Cap:
€ 1.92B ($ 2.14B)
Enterprise V:
€ 2.88B ($ 3.22B)
Volume:
-
Avg Vol (2M):
-
Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Fortrea Holdings Inc ( ) from 2023 to Sep 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Fortrea stock (FRA:K67) PE ratio as of Sep 22 2024 is 0. More Details

Fortrea Holdings Inc (FRA:K67) PE Ratio (TTM) Chart

To

Fortrea Holdings Inc (FRA:K67) PE Ratio (TTM) Historical Data

Total 300
  • 1
  • 2
  • 3
  • 4
Fortrea PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-09-22 At Loss 2024-07-22 At Loss
2024-09-20 At Loss 2024-07-19 At Loss
2024-09-19 At Loss 2024-07-18 At Loss
2024-09-18 At Loss 2024-07-17 At Loss
2024-09-17 At Loss 2024-07-16 At Loss
2024-09-16 At Loss 2024-07-15 At Loss
2024-09-13 At Loss 2024-07-12 At Loss
2024-09-12 At Loss 2024-07-11 At Loss
2024-09-11 At Loss 2024-07-10 At Loss
2024-09-10 At Loss 2024-07-09 At Loss
2024-09-09 At Loss 2024-07-08 At Loss
2024-09-06 At Loss 2024-07-05 At Loss
2024-09-05 At Loss 2024-07-04 At Loss
2024-09-04 At Loss 2024-07-03 At Loss
2024-09-03 At Loss 2024-07-02 At Loss
2024-09-02 At Loss 2024-07-01 At Loss
2024-08-30 At Loss 2024-06-28 At Loss
2024-08-29 At Loss 2024-06-27 At Loss
2024-08-28 At Loss 2024-06-26 At Loss
2024-08-27 At Loss 2024-06-25 At Loss
2024-08-26 At Loss 2024-06-24 At Loss
2024-08-23 At Loss 2024-06-21 At Loss
2024-08-22 At Loss 2024-06-20 At Loss
2024-08-21 At Loss 2024-06-19 At Loss
2024-08-20 At Loss 2024-06-18 At Loss
2024-08-19 At Loss 2024-06-17 At Loss
2024-08-16 At Loss 2024-06-14 At Loss
2024-08-15 At Loss 2024-06-13 At Loss
2024-08-14 At Loss 2024-06-12 At Loss
2024-08-13 At Loss 2024-06-11 At Loss
2024-08-12 At Loss 2024-06-10 At Loss
2024-08-09 At Loss 2024-06-07 At Loss
2024-08-08 At Loss 2024-06-06 At Loss
2024-08-07 At Loss 2024-06-05 At Loss
2024-08-06 At Loss 2024-06-04 At Loss
2024-08-05 At Loss 2024-06-03 At Loss
2024-08-02 At Loss 2024-05-31 At Loss
2024-08-01 At Loss 2024-05-30 At Loss
2024-07-31 At Loss 2024-05-29 At Loss
2024-07-30 At Loss 2024-05-28 At Loss
2024-07-29 At Loss 2024-05-27 At Loss
2024-07-26 At Loss 2024-05-24 At Loss
2024-07-25 At Loss 2024-05-23 At Loss
2024-07-24 At Loss 2024-05-22 At Loss
2024-07-23 At Loss 2024-05-21 At Loss

Fortrea Holdings Inc (FRA:K67) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Fortrea Holdings Inc
NAICS : 541715 SIC : 2834
ISIN : US34965K1079

Share Class Description:

FRA:K67: When Issue
Description
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.